Research

1. The utility of genetic risk variants for prostate cancer as biomarkers of progression and severity.
2. Studying the molecular bases of the occurrence of renal cancer with the possibility of validating new biomarkers with clinical, diagnostic, and prognostic utility.
3. The study of how patients with metastasized renal cancer respond to treatment with the most used current drugs.
4. Genetic risk variants in the evolution of superficial bladder cancer towards recurrence and progression.
5. HLA and prognosis in oncology (colon cancer, breast cancer, lung cancer).
6. Immunotherapy in bladder cancer.
7. The role of tumor immunogenetics in diagnosis and monitoring different types of cancer.

– Oncogenes and the expression of HLA alleles in different types of cancer (kidney cancer, bladder carcinoma, adenocarcinoma of the colon, lung cancer, breast cancer, cervical cancer, liver cancer, etc.). The effectiveness of cellular immunity stimulation in different types of cancer.

8. Immunogenetics of aging.
9. Molecular genetic, immunological diagnosis and prediction of response to immunosuppressive therapy in solid organ transplantation.
10. Immunological reconstitution and chimerism – essential parameters in the post-bone marrow transplant evaluation.
11. The virtual crossmatch – clinical, immunogenetic, and prognostic aspects in renal transplantation.
12. Molecular Biology of sub-clinical and clinical acute rejection in solid organ transplantation.
13. Molecular Biology of GVHD after transplantation of peripheral hematopoietic cells.